J P Morgan Chase & Co reissued their overweight rating on shares of Shire PLC (LON:SHP) in a research note published on Monday, Marketbeat reports. They currently have a GBX 5,300 ($69.94) price target on the biopharmaceutical company’s stock.
Other analysts have also recently issued research reports about the stock. Deutsche Bank AG restated a buy rating and issued a GBX 6,000 ($79.18) target price on shares of Shire PLC in a research note on Friday, August 4th. Jefferies Group LLC cut their price target on shares of Shire PLC from GBX 5,600 ($73.90) to GBX 5,250 ($69.28) and set a buy rating for the company in a report on Monday, August 7th. Societe Generale reiterated a buy rating and issued a GBX 7,500 ($98.97) price target on shares of Shire PLC in a report on Wednesday, July 12th. Shore Capital reiterated a buy rating on shares of Shire PLC in a report on Wednesday, July 19th. Finally, Berenberg Bank reiterated a buy rating and issued a GBX 6,000 ($79.18) price target on shares of Shire PLC in a report on Wednesday, August 9th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of GBX 5,509.68 ($72.71).
ILLEGAL ACTIVITY WARNING: “Shire PLC (SHP) Stock Rating Reaffirmed by J P Morgan Chase & Co” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/03/shire-plc-shp-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.
In related news, insider Anne Minto purchased 190 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The stock was acquired at an average price of GBX 3,785 ($49.95) per share, for a total transaction of £7,191.50 ($9,489.97). Also, insider Flemming Ornskov purchased 8,400 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average price of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.